Introduction
The Hh pathway is critical for cell proliferation and morphogenesis at many stages of embryogenesis and postnatal development (1, 2) . In addition to the importance of Hh signaling in development, Hh signal transduction is disrupted in many types of cancer (3) . A genetic screen for genes functioning in mouse gastrulation revealed that mutations in several genes necessary for primary cilium formation, transport and function are associated with mouse phenotypes suggestive of deficient Sonic hedgehog (SHH) signaling (4) . Several Hh transduction proteins are localized within primary cilia, so these results together with the genetic data support a view of primary cilia as transduction centers for Hh signaling.
In the absence of a Hh ligand, PTCH receptor localizes in cilia of NIH3T3 cells (5) . When SHH binds to PTCH, PTCH disappears from the cilia, enabling the seven transmembrane-domain protein SMOOTHENED (SMO) to enter cilia (6) . SMO inhibits the function of the protein SUFU, which in turn controls the processing and/or transport of GLI transcription factors. SUFU and the three types of GLI protein (GLI1-3) are readily detected at distal tips of cilia (7) . After Hh inactivates PTCH and causes SMO to move into cilia, a SMO-triggered change in GLI processing allows movement of activating forms of GLI proteins into the nucleus, where they induce transcription of target genes (5, 6, 8) . Although most or all of the Hh pathway components are present in cilia, most are present and at least some are functional in other parts of the cell (9, 10) .
For this reason, it is possible that some Hh transduction occurs outside cilia.
Primary cilia are cell cycle phase-specific organelles that extend from the maternal centriole. They frequently act as sensors of mechanical and chemical signals (11) . Growing cells have primary cilia during S-phase, but disassemble the appendage prior to each cell division. In G 2 and M phases, cilium shortening occurs, leading to eventual cilium resorption or release from the plasma membrane (12) . Cells exiting the cell cycle form new cilia. Ciliogenesis and cilium maintenance rely upon transport of axoneme assembly components to the extending tip of the cilium. This intraflagellar transport (IFT) requires motor and adaptor proteins for trafficking in anterograde (toward the tip or positive microtubule end) and retrograde (toward the negative microtubule end) directions. Cilium components and signal transduction proteins are transported as parts of multimeric protein complexes called IFT particles (13) . KINESIN-2, which is a complex of KIF3a, KIF3b and KINESIN-2-associated proteins, moves IFT particles and their protein cargoes along the axoneme toward the ciliary tip (13) . Mutations in Kif3a block Hh signal transduction during normal development (14) . In the present study, we analyzed the effect of Kif3a mutation on initiation and maintenance of Hh pathway-driven cerebellar tumors.
SHH controls cell division in the mouse cerebellum. Granule neuron precursors (GNPs) in the external germinal layer of the cerebellum proliferate (15) , stimulated by SHH transmitted by Purkinje neurons (16) (17) (18) . The newly formed granule neurons extend axons that synapse with Purkinje cell dendrites in the molecular layer, whereas granule neuron cell bodies migrate from the external germinal layer through the layer containing Purkinje cell bodies to the internal granule layer (15) . The buildup of PTCH in GNPs in response to SHH may restrain ongoing SHH signaling by binding ligand and by inhibiting SMO, perhaps contributing to the cessation of GNP production that normally occurs in mice about 2 weeks after birth. In keeping with that idea, loss of restraining Hh pathway proteins such as SUFU or PTCH can lead to medulloblastoma (MB), a cancer arising from unrestrained growth of GNPs that is the most common malignant childhood brain tumor.
MBs have multiple causes including altered Hh or Wnt signaling (19) . The initial identification of damage to the Hh pathway as a cause of MB arose when mutations in human PTCH were discovered to cause Gorlin's syndrome, a birth defects syndrome with associated high rates of MB (20, 21) . When growth restraint by PTCH is genetically reduced, as in the Ptch +/− mouse model of Gorlin's syndrome, some GNPs continue to proliferate beyond the usual time. The consequence can be formation of preneoplastic lesions and MB (22) . The importance of Hh target genes for MBs is also supported by the inhibition of MB growth that occurs when Hh signal transduction is blocked by cyclopamine (23) . In humans, MB formation appears to occur over the course of years, probably beginning with a mutant GNP during cerebellum development (birth to 1 year of age), and typically leading to symptomatic MB at about 7 years of age (24) . In mice predisposed to spontaneous tumorigenesis, such as Ptch +/− heterozygous mice, formation of tumors including MB occurs in some mice within the first months of life (22) .
The discovery of the importance of primary cilia for Hh signal transduction led to the discovery that cilia are important for early stages of cerebellum development (25, 26) . Pioneering ultrastructure studies of MBs identified primary cilia on their cell surfaces as well (27) . Mouse models of MB used to investigate the role of cilia in tumor initiation have given complex results. Cilia are required for growth of tumor cells that have constitutive Hh target gene transcription due to hyperactive SMO, but cilia restrain growth of tumor cells when target gene activation occurs in response to a mutant Gli2 (28) .
Among the several mouse models of MB, only one, Ptch heterozygous mice, has the same genetic cause as Gorlin syndrome (22) . Here, we investigate the role of Kif3a in tumorigenesis in these mice. We deleted Kif3a from the GNP cells, the cell type of origin for spontaneous MB. Cultured MB cells and an allograft mouse model of MB were used to probe the role of KIF3a in growing tumor cells and in established tumors. In this way, we tested whether interference with cilia formation can arrest or reverse tumors that had already started to grow, a situation analogous to newly diagnosed human MB patients.
Materials and methods

MB cell line derivation
MB cell lines were produced using an adapted serial dissociation protocol (29) modified to include an initial serum-free neurobasal medium culture for 2 days followed by 24 h serial dissociation of MB tissue using collagenase, dispase and hyaluronidase. Immortalization was carried out by serial passaging and confirmation of stable Shh pathway target gene expression after every fifth passage. Cell lines were deemed immortalized after 25 passages.
Cell culture GNP preparation and culture was carried out as described previously (16) . For Kif3a ablation in fibroblasts, Kif3a fl/fl MEFs were derived in our laboratory from a mouse engineered to have loxP sites surrounding the Kif3a gene. A Cre recombinase fused to a modified estrogen receptor (ER) was then delivered into the cell line by retroviral infection. For ciliation studies, cells were treated as described previously (5) except the MB cell lines were starved in 0% fetal bovine serum. Cells were transfected with Gli2-Flag construct (obtained from C.C.Hui) using Lipofectamine 2000 (Invitrogen) per the manufacturer's provided instructions. In vitro tamoxifen treatment was carried out using 4-OH tamoxifen (CalBiochem). The PZP53 MB cell line was obtained from P.Beachy (23) . The mouse colon carcinoma cell line CT26 was obtained from ATCC (CRL2638).
Antibodies
Anti-p38 and anti-Kif3a were purchased from Abcam (ab7952, ab11259), antiGli1 from Cell Signaling Technologies (L42B10), anti-acetylated tubulin from Sigma (T6793) and Hoechst/DAPI stain from Sigma (D9542). Secondary antibodies conjugated to horseradish peroxidase were from Jackson Laboratories. Anti-Ptch1 rabbit polyclonal antibody and anti-Smo rabbit polyclonal antibodies have been described (5) . Standard hematoxylin and eosin (H&E) staining was used for tissue samples. Microscopy was performed using a Leica (DMIL) brightfield photomicroscope and a Leica confocal microscope (Leica DMIRE2). Images were assembled using Adobe Photoshop CS4 and brightness/contrast were adjusted for optimal viewing; any manipulation was applied to the entire image.
Quantitative PCR Cellular RNA was isolated using Trizol (Invitrogen). cDNA was prepared using SuperScript III First Strand Kit (Invitrogen). Real-time (quantitative) PCR (Bio-Rad) was used to measure and quantify transcript levels. TaqMan (Applied Biosystems) gene expression probes used were Mm00970977_ m1 (ptch1), Mm00494645_m1 (gli1), Mm00257977_m1 (gli2) and Mm99999915_g1 (gapdh for establishment of baseline).
Cell lysate preparation and western blot analysis
For the production of whole-cell, cerebellum and GNP lysates, cells were lysed in 50 mM Tris at pH 7.4, 300 mM NaCl, 2% NP-40 (v/v), 0.25% deoxycholate (w/v), 10 mM N-ethyl maleimide, 1 mM dithiothreitol and protease inhibitor cocktail (ethylenediaminetetraacetic acid-free, Roche).
Mice
All mouse procedures were approved by the Stanford International Animal Care and Use Committee (APLAC Protocol 10424, 10412). Genetically modified mice Ptch +/− (108B2 line) were generated in our laboratory (22); 4-6-week-old Nude/Nude mice were obtained from Charles River Labs; other mice were obtained from laboratories listed in the indicated references: Kif3a fl/fl (30) and Math1-Cre ER (31) . For genotyping, ear clips and/or tail clips were digested in Proteinase K (Invitrogen)-containing buffer; 2 µl was used to run PCR (38 cycles of 95°C for 30 s denaturing, 52°C for 30 s annealing, 70°C for extension).
Induction of Cre recombinase activity in GNPs in the cerebellum was accomplished by administration of tamoxifen (32) . Tamoxifen (Sigma) was dissolved in corn oil (Sigma) at 5 mg/ml at 37°C, filter sterilized and stored for up to 7 days at 4°C in the dark. A gavage syringe appropriate to mouse esophageal size was used to administer tamoxifen to pups at a dose of 3-4 mg/40 g body weight (calculated based on the average pup size) on postnatal days 1 and 4. Tamoxifen was administered to adult nude mice at a dose of 8 mg/40 g body weight. An equivalent volume of sterile filtered corn oil alone was used for vehicle treatment groups.
Tumorigenesis and cell survival assays
Nude mice received cell injections: 800 000 cells per flank or shoulder for the experiment documented in Figure 2 (n = 6) and 1.6 million cells per flank or shoulder for all other heterotopic tumor assays (n = 8). Following injection, cells were incubated with 1 ml propidium iodide (Sigma; 50 μg/ml in phosphate-buffered saline) and survival was consistently >85%. Tumor size was measured every 3 days with a digital caliper and tumor diameter was calculated using the standard modified ellipse formula (0.5 × length × width 2 ). Orthotopic tumor allografts were carried out using a stereotactic injection system. Forty thousand MB cells in 5 µl phosphate-buffered saline were injected into the central cerebellum. Soft agar transformation assay was performed in 6 cm plates, and 5 × 10 4 cells were added to 3 ml 0.3% LMP agarose (Sigma) with 15% serum + Dulbecco's modified Eagle's medium and plated on top of solidified 0.5% LMP agarose with 15% serum + Dulbecco's modified Eagle's medium. After 18 days, colonies larger than 2 mm were counted. Cell growth rate was determined using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) survival assay (33) . Results of the assay are reported as 'cell growth ratio', a standard normalized optical density value that corrects for absorbance and is reported relative to a single cell type (which is assigned a growth ratio of one). For the MTT assay, cells (3 × 10 3 /well) were plated in 96-well culture plates. Survival was assessed at indicated time points by the addition of 20 μl MTT and incubation for 2 h; absorbance was measured at 570 nm.
Results
Kif3a is necessary for MB tumor initiation
We designed experiments to assess the importance of Kif3a in malignant transformation of GNPs to MB. GNPs, and MB arising from them, characteristically express Math1, which encodes a basic helixloop-helix transcription factor. A Math1 enhancer directing expression of reporter genes in a Math1-specific pattern was reported previously (34) . Math1 expression is restricted to GNPs in the developing cerebellum, with loss of expression upon differentiation into granule neurons (35) . By 2 weeks after birth, mouse pups have little to no detectable Math1 RNA or Math1-driven GFP in the cerebellum. We performed crosses to generate mice with a Math1 enhancer directing production of Cre 
Kif3a
fl/fl mouse cerebella ( Figure 1E ) was sufficient to sustain apparently normal cerebellum development ( Figure 1F ). Cerebella from mice with Kif3a-deficient GNPs were morphologically and histologically indistinguishable from controls. In contrast, mice constitutively lacking KIF3a protein in all hGFAP-expressing cells have severely impaired cerebellum development (28) .
Tamoxifen 
Loss of Kif3a from cultured fibroblasts has no effect on their growth
The inability to form MB in Ptch +/− mice lacking Kif3a in their GNP cells led us to ask whether loss of Kif3a has a general effect on cell growth. Fibroblasts derived from a Kif3a fl/fl Cre-ER mouse (36) were treated with tamoxifen to inactivate the Kif3a gene (Figure 2A -C). KIF3a protein is stable, taking ~8 days to reach minimal levels after tamoxifen treatment ( Figure 2C ). This time course of loss of Kif3a protein correlates with the time course of cilia disappearance. Primary cilia were rarely detected in cells after loss of Kif3a protein ( Figure 2D ) The growth characteristics of fibroblasts with or without tamoxifen was the same ( Figure 2F ). Therefore, KIF3a is dispensable for fibroblast growth in culture. We next tested whether the removal of KIF3a had any discernable effect on the fibroblasts by testing their ability to respond to Hh pathway agonists. Figure 2E, lanes 1-4) . Each agonist induced accumulation of PTCH to at least 10-fold more than the control. Kif3a deletion resulted in a higher level of PTCH in cells not treated with agonist, perhaps due to reduced negative regulation of Hh transduction (37) (Figure 2E, lane 5) . Addition of SHH slightly lowered PTCH protein ( Figure 2E , compare lane 5 with 6), whereas SAG, an agonist that acts directly on Smoothened, caused PTCH to accumulate only about 2-fold more than in the control ( Figure 2E,  lanes 7 and 8) . 20-OH, another inducer, had a similar modest effect. GLI1 is another Hh pathway target gene and GLI1 protein levels follow a trend similar to PTCH protein levels in wild-type fibroblasts and fibroblasts treated with SHH agonist after Kif3a deletion ( Figure 2G ).
These data show that fibroblasts can proliferate normally in the absence of functional KIF3a, as has been reported previously for other cell lines (30, 36) , but fibroblasts lacking KIF3a have an impaired response to Hh pathway agonists.
Loss of Kif3a results in growth arrest of transformed MB cells
Fibroblasts grow without KIF3a, but we show that Kif3a is necessary for initiation of MB, suggesting that these tumor cells are different. In cultured fibroblasts, SHH ligand stimulates transcription of target genes most effectively when cells are contact inhibited (confluent), nutrient restricted (serum deprived) and predominantly quiescent. Under these conditions >90% of NIH3T3 fibroblast-like cells are ciliated. In contrast, cultured MB cells derived from a Ptch +/− mouse MB tumor proliferated relentlessly in conditions of serum deprivation, ignoring contact inhibition and nutrient status cues. Fewer than 10% of cultured, confluent, Ptch +/− MB cells formed cilia when subjected to the standard 24 h serum-restriction protocol, which results in cilia formation in NIH3T3 cells ( Figure 3A) .
To determine the optimal length of time for formation of primary cilia in Ptch +/− MB cells, different times of serum starvation were tested. After 96 h of serum deprivation, 68% of MB cells formed cilia ( Figure 3B ). SMO protein became concentrated in ~59% of the primary cilia in cultured MB cells ( Figure 3C ), consistent with the high level of SHH target gene activity known to occur in MB tumors (22) . Thus, MB cells in culture eventually form primary cilia, but do not ciliate as readily or under the same conditions as cultured NIH3T3 cells. These findings guided our studies of roles of cilia in a newly created MB cell line.
We derived a MB cultured cell line with tumorigenic potential from a Ptch , enabling the deletion of Kif3a using in vitro tamoxifen treatment. After immortalization, the cells had a faster doubling time than fibroblasts ( Figure 4A ), similar to that of a murine colon carcinoma cell line (38) . MB Kif-CreER cells were able to form cilia ( Figure 4B and C) and formed colonies in soft agar ( Figure 4D ).
Anchorage-independent growth is one indicator of the metastatic potential of cells. MB Kif-CreER cells injected into the flanks ( Figure 4E ) or cerebella ( Figure 4F ) of immunodeficient nude mice formed solid tumors. Neuropathological analysis of the flank and cerebellar tumors revealed indistinguishable cytology, except that the cerebellar tumors infiltrated adjacent normal tissue. All the tumors had closely packed, enlarged, undifferentiated cells with high nuclear to cytoplasmic ratios, nuclear molding, frequent mitotic figures and focal necrosis, all features of embryonal central nervous system neoplasms. Immunohistochemistry showed focal GFAP protein accumulation in flank and cerebellar tumors, without detectable synaptophysin or β-catenin staining (Supplementary Figure 3A , available at Carcinogenesis Online). These features are diagnostic of MB.
We tested the role of KIF3a in MB cell survival by treating MB Kif-CreER cells with tamoxifen in vitro. In contrast to fibroblasts, MB cells required Kif3a for their survival in culture. MB Kif-CreER cells underwent growth arrest following tamoxifen treatment, at a time consistent with disappearance of KIF3a and cilia ( Figure 5A ).
Complementation by Gli2 overcomes MB growth arrest associated with the loss of Kif3a
We tested whether the growth arrest of MB cells after inactivation of Kif3a and loss of primary cilia was dependent upon interference with the Hh pathway. The goal was to see whether other pathways that might be affected by Kif3a mutation. If the important effect was upon Hh transduction, it should be possible to rescue the cells by activating SHH target genes. To MB cells lacking Kif3a, we provided GLI2, the major Hh transcriptional activator, to see whether this would overcome the growth arrest. Transfection of Gli2-FLAG (39) at the time of tamoxifen treatment protected tamoxifen-treated MB Kif3a-CreER cells from cell death ( Figure 5B ). GLI2 levels were 4.5-fold higher compared with untransfected, tamoxifen-treated MB KifCreER cells ( Figure 5C ). Five days after tamoxifen treatment, when KIF3a levels were reduced, the MB Kif-CreER cells without added GLI2 had far less GLI1 protein (a SHH target) than control cells where KIF3a remained functional ( Figure 5D ). Signature transcriptional targets of the Wnt, TGF-β, AKT and PDGF signaling pathways were unchanged (Supplementary Figure 2B , available at Carcinogenesis Online). We conclude that the deaths of tamoxifen-treated MB Kif-CreER cells in the absence of added GLI2 was due to the lack of SHH target gene expression. Restoration of active GLI2, and consequently SHH target gene activity, eliminated the need for Kif3a in MB Kif-CreER cell survival.
Loss of Kif3a results in growth arrest of established MB tumors
We used mouse allografts to learn how loss of KIF3a affects alreadyestablished MB tumors. Due to the time it takes for tamoxifen to reduce Kif3a protein levels compared with the rapid rate of growth of MB and consequential rapid mortality from intracranial MB, these experiments could only be done with flank tumors but not with intracranial tumors. This situation is akin to a newly diagnosed pediatric patient carrying a MB, in contrast to experiments described above that show KIF3a is required to form MBs. MB
Kif-CreER cells were tested for their ability to exhibit anchorage-dependent growth by growing them in soft agar in the presence or absence of tamoxifen. Tamoxifen prevented the cells from forming colonies in soft agar ( Figure 6A and B) . To ensure that tamoxifen did not have a general toxic effect, murine colon cancer cells were treated with tamoxifen. They formed colonies at the same rate as untreated cells (Supplementary Figure 4A Figure 6D ). Vehicle-treated tumors continued to grow. In mice that underwent tamoxifen treatment, and consequently inactivation of Kif3a in Math1-expressing MB cells, flank tumors had necrotic tissue with lower cell density, interspersed with regions of necrosis and fibrosis ( Figure 6E ).
Discussion
Primary cilia in cerebellum development and MB
Among several mouse models of MB, only one has the same genetic lesion as human Gorlin syndrome, which is due to PTCH haploinsufficiency (22, 40) . The sequence and frequency of events in the human neoplastic transformation of a GNP to MB is preserved in the Ptch +/− heterozygous mouse model of MB. About 15% of mice that are heterozygous for a null Ptch mutation develop MB by 5 months of age (22, 40) . The tumors arise sporadically, spontaneously and focally in mice with a mature cerebellum and are histologically similar to human MB. Ptch +/− mice recapitulate the human Gorlin syndrome in that tumors occur in association with basal cell carcinoma and rhabdomyosarcoma (22) . Non-Gorlin syndrome mouse models of Hh pathway-driven MB have been engineered to activate Hh targets in all GNPs by conditional loss-of-function of both alleles of PTCH (41) or by introducing an activating Smo M2 or Smo A2 allele (42) . Tumors that develop in these other mouse models differ from each other and from human Gorlin syndrome-associated tumors. Both models rely upon tissue-specific drivers and result in unrestrained proliferation of GNPs, culminating by 2 months of age in extensive lesions that encase the cerebellum in 90-100% of mice (41, 42) . These genetic alterations, and the tumors that arise from them, do not represent the usual sequence of events that occurs in pediatric MB.
Han et al. (28) studied the need for Kif3a in central nervous system tumors, including MB, using an activated Smo allele or a GLI2 constitutively active (CA) model. Our findings are consistent with theirs in that Hh pathway-driven MBs do not develop without functional primary cilia. Their study employed conditional Kif3a mutant mice that express Cre recombinase controlled by the hGFAP driver, which stimulates recombination in GNPs, all neural stem cells, and many neurons and ependymal cells (43) . Tumors that developed in the Smo M2 mouse brains were highly malignant, encasing the majority of developing cerebellum folia by postnatal day 10 (28) . Tumors that developed in Gli2-CA mice occurred much later in life, were distributed throughout the central nervous system and had high expression levels of Hh and WNT target genes (28) . The authors concluded that cilia can either promote or inhibit Hh-driven brain tumors and basal cell carcinoma, depending on how the Hh pathway is activated, with tumor promotion occurring in the Gli2-CA model and tumor suppression occurring in the Smo M2 model (28,44). 
←
Cilia and Kif3a disruption specifically targeted to GNPs has not been reported prior to the present study. The precise roles of cilia in the developing cerebellum and in tumor cells remain a mystery, especially because MB cells have primary cilia only for the brief interval when they are not actively cycling. That appears to be time enough for the cilia to aid transduction processes, perhaps allowing modification of Hh-transducing protein structures, associations, modifications or transport. Many Hh pathway-related functions have been proposed for cilia and the components of IFT that build cilia, but the precise role(s) of cilia in Hh signal transduction remains uncertain.
Relationship of GLI proteins and KIF3a tested by epistasis
GLI proteins mediate Hh pathway output, with GLI1 and GLI2 acting as transcriptional activators and GLI3 acting as an activator of transcription in its full-length form and a repressor of transcription in its processed form. With insufficient amounts of KIF3a, processing of GLI3 from its full-length activator form to its truncated repressor form is disrupted in fibroblasts (4, 37, 45, 46) . Loss of Kif3a prevents formation of cilia and blocks efficient formation of the repressor form of GLI3, resulting in constitutive low-level transcription of Hh target genes coupled with an inability to fully activate transcription of Hh target genes ( Figure 2E ).
In our experiments, introduction of additional GLI2 rescued the growth arrest of cultured Kif3a-deficient MB cells ( Figure 5 ). Thus, enforced Hh pathway transcriptional activator expression is sufficient to overcome proliferation impairment caused by Kif3a deficiency. KIF3a localization and function is not limited to the cilium (47) . If the main role of KIF3a in MB Kif-CreER cell growth was facilitation of intracellular trafficking or mitosis, GLI2 should not have been able to rescue proliferation in the cells. GLI2 is unlikely to repair the intracellular trafficking and mitotic deficits that occur upon Kif3a loss; a role for GLI2 in trafficking or mitosis has not been found. If KIF3a had an essential role in mitosis, we would expect cells lacking KIF3a to have mitotic and/or proliferation deficits. Fibroblasts lacking KIF3a (Figure 4 ) grew well, demonstrating that Kif3a is not essential for fibroblast proliferation or survival. KIF3a-deficient fibroblasts do not exhibit intracellular trafficking or mitosis defects (36) (data not shown). We conclude that the reason mutated Kif3a or an altered primary cilium affects tumorigenicity is because they are required for proper Hh target gene activation, not because of mitotic or intracellular transport defects.
MB cells and fibroblasts both require cilia for Hh target genes to be active despite the differences in how those genes are activated. MB cells have active SHH target genes due to loss of the target-repressing effect of PTCH receptor, a condition that obviates any need for a SHH signal. Nonetheless, cilia are required for the target genes to remain active. Fibroblasts turn on target genes in response to a SHH ligand, but cannot do so if they lack IFT components and cilia ( Figure 4E ) (48) . The target genes in MB cells could in theory have remained active and capable of sustaining Hh pathway-driven tumor formation without any need for cilia. Our results and Han et al. (28) . show the contrary: cilia are continuously necessary for proper SHH target gene 
